Objective:To assess the feasibility ,safety and short‐term outcome of simultaneous integrated boost‐intensity modulated radiation therapy(SIB‐IMRT) with concurrent capecitabine chemotherpay for anal cancer .Methods:A total of 10 hospitalized patients with anal cancer during Sep .2009 and Feb .2014 were treated with SIB‐IMRT .A total dosage of 57 .6 Gy was given to the primary lesion and macroscopical lymph nodes in 32 fractions ,with 1 .8 Gy in each fraction .And a total dosage of 48 Gy was given to the bilateral iliac vessels and inguinal lymphatic drainage region in 32 fractions ,with 1 .5 Gy in each fraction .And capecitabine was concurrently administered at the oral dose of 625 mg/m2 ,twice daily ,5 days per week . Two patients received a sequential radiation boost dose of 2 × 1 .8 Gy due to macroscopic residual lesion at week 5 of treatment . Acute and late adverse reaction was assessed according to the Common Terminology Criteria for Adverse Events version 4 .0 . Results:All patients completed radio‐chemotherapy without any treatment break .The incidence rate of grade 3 skin adverse reaction was 50% (5/10) .No grade 4 adverse reaction was observed .Mean follow‐up was 20 months(range 6‐60 months) .The 2‐year‐local control ,colostomy‐free survival ,distant metastases‐free survival and overall survival rates were 100% (10/10) ,90%(9/10) ,90% (9/10) ,and 90% (9/10) ,respectively .Conclusions:SIB‐IMRT with concurrent capecitabine chemotherapy :an acceptable safe regimen ,however ,more samples and a longer follow‐up are required to assess its potential superiority .